Human epidermal growth factor receptor dimerization analysis in breast cancer diagnosis: Potential for improving testing accuracy and treatment selection

Molecular Diagnosis and Therapy

Volumn 13, Issue 6, 2009, Pages 359-365

  Spears, Melanie ^a   Bartlett, John M S ^a  

^a WESTERN GENERAL HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CAPECITABINE; CARBOPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; GAMMA UROGASTRONE; GEFITINIB; LAPATINIB; MONOCLONAL ANTIBODY; PERTUZUMAB; TRASTUZUMAB;

BIOASSAY; BIOLUMINESCENCE RESONANCE ENERGY TRANSFER; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER RELAPSE; CANCER THERAPY; CLINICAL TRIAL; DIMERIZATION; DRUG MECHANISM; DRUG RESPONSE; DRUG SENSITIVITY; DRUG TARGETING; FLUORESCENCE RESONANCE ENERGY TRANSFER; GENE AMPLIFICATION; HUMAN; IMMUNOHISTOCHEMISTRY; PREDICTION; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; PROXIMITY LIGATION ASSAY; REVIEW;

EID: 70450263444     PISSN: 11771062     EISSN: 11792000     Source Type: Journal    
DOI: 10.1007/BF03256341     Document Type: Review

References (60)

1. Ross JS. Fletcher JA. The HER-2/neu oncogene in breast cancer: prognostic factor, predictive factor, and target for therapy. Stem Cells 1998; 16 (6): 413-428 (Pubitemid 28524507)
2. Slamon DJ, Clark GM, Wong SG, et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987;235(4785): 177-182
3. Yarden Y. The EGFR family and its ligands in human cancer: signalling mechanisms and therapeutic opportunities. Eur J Cancer 2001 ; 37 Suppl. 4: S3-8 (Pubitemid 32938123)
4. Yarden Y, Sliwkowski MX. Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2001; 2 (2): 127-137
5. Zwick EJ, Bange J, Ullrich A. Receptor tyrosine kinase signalling as a target for cancer intervention strategies. Endocr Relat Cancer 2001; 8 (3): 161-173 (Pubitemid 32947638)
6. Yarden Y, Baselga J, Miles D. Molecular approach to breast cancer treatment. Semin Oncol 2004: 31 (5 Suppl. 10): 6-13 (Pubitemid 39370104)
7. Hynes NE, Horsch K, Olayioye MA, et al. The ErbB receptor tyrosine family as signal integrators. Endocr Relat Cancer 2001; 8 (3): 151-159 (Pubitemid 32947637)
8. Olayioye MA. Update on HER-2 as a target for cancer therapy: intracellular signaling pathways of ErbB2/HER-2 and family members. Breast Cancer Res 2001; 3 (6): 385-389
9. Graus-Porta D, Beerli RR. Daly JM, et al. ErbB-2, the preferred hetero- dimerization partner of all ErbB receptors, is a mediator of lateral signaling. EMBOJ 1997; 16(7): 1647-1655 (Pubitemid 27151960)
10. Klapper LN, Glathe S, Vaisman N, et al. The ErbB-2/HER2 oncoprotein of human carcinomas may function solely as a shared coreceptor for multiple stroma-derived growth factors. Proc Natl Acad Sci U S A 1999; 96 (9): 4995-5000 (Pubitemid 29214524)
11. Citri A, Skaria KB, Yarden Y. The deaf and the dumb: the biology of ErbB-2 and ErbB-3. Exp Cell Res 2003; 284 (1): 54-65 (Pubitemid 36342255)
12. Bagossi P, Horvath G, Vereb G, et al. Molecular modeling of nearly full-length ErbB2 receptor. Biophys J 2005; 88 (2): 1354-1363 (Pubitemid 40975962)
13. Burgess AW, Cho HS, Eigenbrot C, et al. An open-and-shut case? Recent insights into the activation of EGF/ErbB receptors. Mol Cell 2003; 12 (3): 541-552 (Pubitemid 37222478)
14. Citri A, Gan J, Mosesson Y, et al. Hsp 90 restrains ErbB-2/HER2 signalling by limiting heterodimer formation. EMBO Rep 2004; 5 (12): 1165-1170 (Pubitemid 40103611)
15. Guy PM, Platko JV, Cantley LC, et al. Insect cell-expressed pl80erbB3 possesses an impaired tyrosine kinase activity. Proc Natl Acad Sci U S A 1994; 91 (17): 8132-8136
16. Witton CJ, Reeves JR, Going JJ, et al. Expression of the HER1-4 family of receptor tyrosine kinases in breast cancer. J Pathol 2003: 200 (3): 290-297 (Pubitemid 36827302)
17. Naresh A, Long W, Vidal GA, et al. The ERBB4/HER4 intracellular domain 4ICD is a BH3-only protein promoting apoptosis of breast cancer cells. Cancer Res 2006; 66 ( 12): 6412-6420
18. Vidal GA, Clark DE, Marrero L, et al. A constitutively active ERBB4/HER4 allele with enhanced transcriptional coactivation and cell-killing activities. Oncogene 2007; 26(3): 462-466 (Pubitemid 46122836)
19. Vidal GA, Naresh A, Marrero L, et al. Presenilin-dependent gamma-secretase processing regulates multiple ERBB4/HER4 activities. J Biol Chem 2005; 280(20): 19777-19783 (Pubitemid 41379503)
20. Pianetti S, Arsura M, Romieu-Mourez R, et al. Her-2/neu overexpression induces NF-kappaB via a PI3-kinase/Akt pathway involving calpain-mediated degradation of IkappaB-alpha that can be inhibited by the tumor suppressor PTEN. Oncogene 2001; 20 (11): 1287-1299 (Pubitemid 32269934)
21. Olayioye MA, Neve RM, Lane HA, et al. The ErbB signaling network: receptor heterodimerization in development and cancer. EMBO J 2000: 19 (13): 3159-3167
22. Bhargava R, Gerald WL, Li AR, et al. EGFR gene amplification in breast cancer: correlation with epidermal growth factor receptor mRN A and protein expression and HER-2 status and absence of EGFR-activating mutations. Mod Pathol 2005; 18 (8): 1027-1033 (Pubitemid 41224492)
23. Baulida J. Kraus MH, Alimandi M, et al. All ErbB receptors other than the epidermal growth factor receptor areendocytosis impaired. J Biol Chem 1996; 271 (9): 5251-5257 (Pubitemid 26075021)
24. Hellyer NJ, Cheng K, Koland JG. ErbB3 (HER3) interaction with the p85 regulatory subunit of phosphoinositide 3-kinase. Biochem J 1998; 333 (Pt 3): 757-763 (Pubitemid 28398546)
25. Karunagaran D, Tzahar E, Beerli RR, et al. ErbB-2 is a common auxiliary subunit of NDF and EGF receptors: implications for breast cancer. EMBO J 1996; 15 (2): 254-264 (Pubitemid 26029205)
26. Beerli RR, Graus-Porta D, Woods-Cook K, et al. Neu differentiation factor activation of ErbB-3 and ErbB-4 is cell specific and displays a differential requirement for ErbB-2. Mol Cell Biol 1995; 15 (12): 6496-6505
27. Spencer KS, Graus-Porta D, Leng J, et al. ErbB2 is necessary for induction of carcinoma cell invasion by ErbB family receptor tyrosine kinases. J Cell Biol 2000; 148 (2): 385-397 (Pubitemid 30078250)
28. Olayioye MA, Graus-Porta D, Beerli RR, et al. ErbB-1 and ErbB-2 acquire distinct signaling properties dependent upon their dimerization partner. Mol Cell Biol 1998: 18 (9): 5042-5051 (Pubitemid 28388087)
29. Olayioye MA, Beuvink I, Horsch K, et al. ErbB receptor-induced activation of stat transcription factors is mediated by Src tyrosine kinases. J Biol Chem 1999; 274 (24): 17209-17218 (Pubitemid 129519056)
30. Holbro T, Beerli RR, Maurer F, et al. The ErbB2/ErbB3 heterodimer functions as an oncogenic unit: ErbB2 requires ErbB3 to drive breast tumor cell proliferation. Proc Natl Acad Sci U S A 2003; 100 (15): 8933-8938 (Pubitemid 36899201)
31. Alimandi M, Romano A, Curia MC, et al. Cooperative signaling of ErbB3 and ErbB2 in neoplastic transformation and human mammary carcinomas. Oncogene 1995: 10(9): 1813-1821
32. Cohen BD, Kiener PA, Green JM, et al. The relationship between human epidermal growth-like factor receptor expression and cellular transformation in NIH3T3 cells. J Biol Chem 1996; 271 (48): 30897-30903 (Pubitemid 26404114)
33. Wallasch C, Weiss FU, Niederfellner G, et al. Heregulin-dependent regulation of HER2/neu oncogenic signaling by heterodimerization with HER3. EMBO J 1995; 14 (17): 4267-4275
34. Zhang K, Sun J, Liu N, et al. Transformation of NIH 3T3 cells by HER3 or HER4 receptors requires the presence of HER1 orHER2. J Biol Chem 1996; 271 (7): 3884-3890 (Pubitemid 26065710)
35. Shepard HM. Lewis GD. Sarup JC, et al. Monoclonal antibody therapy of human cancer: taking the HER2 protooncogene to the clinic. J Clin Immunol 1991; 11 (3): 117-127
36. Cho HS, Mason K, Ramyar KX, et al. Structure of the extracellular region of H ER2 alone and in complex with the Herceptin Fab. Nature 2003; 421 (6924): 756-760 (Pubitemid 36227628)
37. Tokunaga E, Oki E, Nishida K, et al. Trastuzumab and breast cancer: devel- opments and current status. Int J Clin Oncol 2006; 11 (3): 199-208 (Pubitemid 44087118)
38. Carter P, Presta L, Gorman CM. et al. Humanization of an anti-p185HER2 antibody for human cancer therapy. Proc Natl Acad Sci U S A 1992; 89 (10): 4285-4289
39. Baselga J. Herceptin alone or in combination with chemotherapy in the treatment of HER2-positive metastatic breast cancer: pivotal trials. Oncology 2001; 61 Suppl. 2: 14-21 (Pubitemid 33033420)
40. Baselga J. Clinical trials of Herceptin (trastuzumab). Eur J Cancer 2001; 37 Suppl. 1: S18-24
41. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 2005; 353(16): 1659-1672
42. Robert NJ, Eiermann W, Pienkowski T, et al. BCIRG 006: docetaxel and trastuzumab-based regimens improve DFS and OS over AC-T in node positive and high risk node negative HER2 positive early breast cancer patients: quality of life (QOL) at 36 months follow-up [abstract no. 19647]. J Clin Oncol 2007; 25 (18 Suppl.): 719s [online]. Available from URL: http://meeting. ascopubs.org/cgi/content/abstract/25/18-suppl ' 19647 [Accessed 2009 Oct 23]
43. Moy B, Kirkpatrick P, Kar S, et al. Lapatinib. Nat Rev Drug Discov 2007; 6 (6): 431-432
44. Geyer CE, Forster J, Lindquist D, et al. Lapatinib plus capecitabine for HER2positive advanced breast cancer. N Engl J Med 2006: 355 (26): 2733-2743
45. Cameron D. Casey M. Press M, et al. A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses. Breast Cancer Res Treat 2008; 112 (3): 533-543
46. Amould L., Arveux P, Couturier J, et al. Pathologic complete response to trastuzumab-based neoadjuvant therapy is related to the level of HER-2 amplification. Clin Cancer Res 2007; 13 (21): 6404-6409
47. Ross JS, Slodkowska EA. Symmans WF, et al. The HER-2 receptor and breast cancer: ten years of targeted anti-HER-2 therapy and personalized medicine. Oncologist 2009; 14 (4): 320-368
48. Nahta R. Yuan LX, Zhang B, et al. Insulin-like growth factor-I receptor/ human epidermal growth factor receptor 2 heterodimerization contributes to trastuzumab resistance of breast cancer cells. Cancer Res 2005; 65 (23): 11118-11128
49. Lu Y, Zi X, Zhao Y, et al. Insulin-like growth factor-I receptor signaling and resistance to trastuzumab (Herceptin). J Natl Cancer Inst 2001: 93 (24): 1852-1857
50. Hudelist G, Köstler WJ, Attems J, et al. Her-2/neu-triggered intracellular tyrosine kinase activation: in vivo relevance of ligand-independent activation mechanisms and impact upon the efficacy of trastuzumab-based treatment. Br J Cancer 2003;89(6):983-991
51. Desmedt C., Sperinde J, Piette F, et al. Quantitation of HER2 expression or HER2: HER2 dimers and differential survival in a cohort of metastatic breast cancer patients carefully selected for trastuzumab treatment primarily by FISH. Diagn Mol Pathol 2009; 18 (1): 22-29
52. Ciruela F. Fluorescence-based methods in the study of protein-protein interactions in living cells. Curr Opin Biotechnol 2008; 19 (4): 338-343
53. Kenworthy AK. Imaging protein-protein interactions using fluorescence resonance energy transfer microscopy. Methods 2001 ; 24 (3): 289-296 (Pubitemid 32846434)
54. Cohen EE. Rosen F, Stadler WM, et al. Phase II trial of ZD 1839 in recurrent or metastatic squamous cell carcinoma of the head and neck. J Clin Oncol 2003; 21 (10): 1980-1987
55. Vogel CL. Cobleigh MA. Tripathy D, et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 2002; 20 (3): 719-726 (Pubitemid 34111379)
56. Kong A, Calleja V, Leboucher P, et al. HER2 oncogenic function escapes EGFR tyrosine kinase inhibitors via activation of alternative HER receptors in breast cancer cells. PLoS ONE 2008; 3 (8): e2881
57. Shi Y, Huang W, Tan Y, et al. A novel proximity assay for the detection of proteins and protein complexes: quantitation of HER1 and HER2 total protein expression and homodimerization in formalin-fixed, paraffinembedded cell lines and breast cancer tissue. Diagn Mol Pathol 2009: 18(1): 11-21
58. Brennan PJ, Kumagai T, Berezov A, et al. HER2/neu: mechanisms of dimerization/oligomerization. Oncogene 2000: 19 (53): 6093-6101
59. Fredriksson S. Gullberg M, Jarvius J, et al. Protein detection using proximitydependent DNA ligation assays. Nat Biotechnol 2002; 20 (5): 473-477 (Pubitemid 34495933)
60. Spears M, Munro AF, Taylor KJ, et al. The use of proximity ligation assay to identify HER2: HER3 heterodimers in early breast cancers [abstract]. Cancer Research 2009: 69 (2 Suppl.): abstract no. 2068